Aptose Biosciences Reports $17.7 Million Net Loss for Nine Months Ended September 30, 2025

Aptose Biosciences Inc. reported a net loss of $17.7 million for the nine months ended September 30, 2025, a decrease from the $23.8 million loss recorded during the same period in 2024. The company did not generate any revenue during this period, consistent with its ongoing status as a clinical-stage biotechnology firm focused on developing precision medicines for oncology. Operating expenses totaled $17.3 million, down from $24.1 million in the previous year, primarily due to reduced research and development costs associated with its lead product candidate, tuspetinib. The basic and diluted loss per share for the nine months was $7.34, compared to $44.41 in the prior year.

Aptose's financial position has deteriorated, with total assets decreasing to $6.3 million as of September 30, 2025, down from $10.1 million at the end of 2024. The company's cash and cash equivalents fell to $0.6 million, alongside restricted cash of $1.0 million. Current liabilities increased significantly to $7.1 million, leading to a working capital deficit of $3.3 million. The accumulated deficit rose to $558.7 million, reflecting the ongoing challenges in achieving profitability and the need for additional financing to support operations.

Strategically, Aptose has focused on advancing its clinical programs, particularly the TUSCANY study, which is evaluating tuspetinib in combination with venetoclax and azacitidine for newly diagnosed acute myeloid leukemia (AML) patients. The company has made progress in its clinical trials, with recent data indicating promising safety and efficacy outcomes. However, the company has also paused the development of luxeptinib due to funding constraints, prioritizing resources for tuspetinib.

Operationally, Aptose's workforce has been reduced, contributing to lower personnel-related expenses. The company has also entered into financing agreements with Hanmi Pharmaceutical Co. Ltd., including a recent Amended Facility Agreement that provides up to $11.9 million for continued clinical development. Despite these efforts, management has expressed substantial doubt about the company's ability to continue as a going concern without securing additional capital, given the adverse market conditions and the challenges faced in raising funds.

Looking ahead, Aptose plans to pursue further financing options to support its clinical trials and operational needs. The company acknowledges the risks associated with its early-stage development status and the potential for delays in clinical studies and regulatory approvals. Management remains focused on advancing its product candidates while navigating the complexities of the biotechnology market.